VFA
RLMD icon

Valeo Financial Advisors’s Relmada Therapeutics RLMD Stock Holding History

Valeo Financial Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$4K – 2038
2020
Q2 		$4K Buy
+100
New +$4.23K ﹤0.01% 1616

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Valeo Financial Advisors's RLMD Position: Q3 2020 in Review

Valeo Financial Advisors sold out of Relmada Therapeutics (RLMD) in Q3 2020, closing a stake of 100 shares — an estimated $4K sold.

Valeo Financial Advisors first reported a position in RLMD in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 72 funds tracked by Wall St. Rank hold RLMD as of Q3 2020.

  • Valeo Financial Advisors reported no remaining Relmada Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Valeo Financial Advisors sold 100 Relmada Therapeutics shares in Q3 2020, an estimated $4K.
  • Valeo Financial Advisors first reported a position in Relmada Therapeutics in Q2 2020 and held it in 1 quarter.
  • Valeo Financial Advisors's Relmada Therapeutics position peaked at $4K in Q2 2020.
  • 72 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2020.

Based on Valeo Financial Advisors's 13F filing for Q3 2020, filed 28 Oct 2020.